We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-7 of 7

Northern exposure?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

The U.S. Prometheus decision and claims to methods of optimizing dosing regimens: Mayo Collaborative Services v. Prometheus Laboratories, Inc., U.S., No. 10-1150

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 11 2012

In a decision last month, the U.S. Supreme Court in a 9-0 ruling has held that the method claims of two patents directed to optimizing the dose of a specific drug for treating an autoimmune disease are not patentable because they merely recite laws of nature

U.S. government now anti-gene patents?

  • Gowling Lafleur Henderson LLP
  • -
  • USA
  • -
  • November 24 2010

The Justice Department of the United States government recently filed an amicus brief in an appeal of a U.S. Federal Court decision regarding the patentability of naturally-occurring DNA sequences, taking the position that that these are not patentable as “part of nature.”

Medical diagnostic claims and Bilski

  • Gowling Lafleur Henderson LLP
  • -
  • USA
  • -
  • September 6 2010

In the long awaited decision in Bilski v. Kappos, the U.S. Supreme Court has concluded that the machine-or-transformation (“MOT”) test is not the sole arbiter of patentable subject matter for “processes” under section 101 of the U.S. Patent Act

Medical diagnostic claims and Bilski

  • Gowling Lafleur Henderson LLP
  • -
  • USA
  • -
  • July 9 2010

In the long awaited decision in Bilski v. Kappos, the U.S. Supreme Court has concluded that the machine-or-transformation (“MOT”) test is not the sole arbiter of patentable subject matter for “processes” under section 101 of the U.S. Patent Act

Life sciences & law current issues 201213

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union, USA
  • -
  • June 18 2012

Each stage of the life cycle of a company or a product presents challenges that demand the expertise and resources of a strong legal partner

Bristol-Myers Squibb Canada Co. et al v. Mylan Pharmaceuticals ULC et al, 2012 FC 1142 (September 27, 2012) efavirenz PM(NOC) case

  • Gowling Lafleur Henderson LLP
  • -
  • USA
  • -
  • September 27 2012

This proceeding brought by Bristol-Myers Squibb Canada Co. and Merck Sharpe & Dohme Corp. (“Applicants”) under the Patented Medicines (Notice of Compliance) Regulations dealt with two patents related to the Applicants’ SUSTIVA (efavirenz) product

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy